Boothbay Fund Management LLC Invests $2.57 Million in TG Therapeutics, Inc. (NASDAQ:TGTX)

Boothbay Fund Management LLC acquired a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 85,360 shares of the biopharmaceutical company's stock, valued at approximately $2,569,000. Boothbay Fund Management LLC owned about 0.05% of TG Therapeutics as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of TGTX. Susquehanna Fundamental Investments LLC acquired a new position in shares of TG Therapeutics during the 4th quarter worth $290,000. Gilder Gagnon Howe & Co. LLC boosted its stake in shares of TG Therapeutics by 25.3% during the 4th quarter. Gilder Gagnon Howe & Co. LLC now owns 81,292 shares of the biopharmaceutical company's stock worth $2,447,000 after acquiring an additional 16,394 shares in the last quarter. Voya Investment Management LLC increased its stake in TG Therapeutics by 398.0% in the 4th quarter. Voya Investment Management LLC now owns 273,739 shares of the biopharmaceutical company's stock valued at $8,240,000 after purchasing an additional 218,766 shares in the last quarter. Penn Capital Management Company LLC purchased a new stake in TG Therapeutics during the fourth quarter worth $10,577,000. Finally, Syon Capital LLC acquired a new stake in TG Therapeutics in the 4th quarter valued at about $276,000. 58.58% of the stock is currently owned by institutional investors and hedge funds.

TG Therapeutics Trading Down 4.3 %

TG Therapeutics stock traded down $1.93 during midday trading on Friday, reaching $43.44. The stock had a trading volume of 4,164,267 shares, compared to its average volume of 3,012,871. The firm's fifty day simple moving average is $38.28 and its two-hundred day simple moving average is $33.05. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. TG Therapeutics, Inc. has a twelve month low of $15.16 and a twelve month high of $46.48. The firm has a market cap of $6.90 billion, a price-to-earnings ratio of -434.36 and a beta of 2.14.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 EPS for the quarter, beating analysts' consensus estimates of $0.08 by $0.07. The firm had revenue of $108.19 million for the quarter, compared to the consensus estimate of $100.67 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. Equities analysts anticipate that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the company. StockNews.com upgraded TG Therapeutics from a "sell" rating to a "hold" rating in a research report on Tuesday, March 4th. HC Wainwright restated a "buy" rating and issued a $55.00 target price on shares of TG Therapeutics in a report on Tuesday, March 4th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $40.67.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.